精氨酸72脯氨酸多态性与卵巢癌风险之间无关联：来自10113名受试者的证据。

No association between Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects.

作者信息

Zhang Anqi, Shi Ting-Yan, Zhao Yuan, Xiang Junmiao, Yu Danyang, Liang Zongwen, Xu Chaoyi, Zhang Qiong, Hu Yue, Wang Danhan, He Jing, Duan Ping

机构信息

Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China.

Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

出版信息

Oncotarget. 2017 Nov 21;8(68):112761-112769. doi: 10.18632/oncotarget.22603. eCollection 2017 Dec 22.

DOI:10.18632/oncotarget.22603

PMID:29348863

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5762548/

Abstract

The gene product is an important regulator of cell growth and a tumor suppressor. The association between Arg72Pro polymorphism and ovarian cancer risk has been widely investigated, but the results are contradictory. We therefore searched the PubMed, EMBASE and Chinese Biomedical databases for studies on the relation between Arg72Pro polymorphism and ovarian cancer risk. Our final meta-analysis included 24 published studies with 3271 cases and 6842 controls. Pooled results indicated that there was no significant association between Arg72Pro polymorphism and ovarian cancer risk [Pro/Pro vs. Arg/Arg: odds ratio (OR) =1.04, 95% confidence interval (CI) = 0.81-1.34; Arg/Pro vs. Arg/Arg: OR = 1.14, 95% CI = 0.96-1.36; recessive: OR = 1.05, 95% CI = 0.90-1.22; dominant: OR = 1.12, 95% CI = 0.94-1.33; and Pro vs. Arg: OR = 1.06, 95% CI=0.93-1.20]. Likewise, stratified analyses failed to reveal a genetic association. Despite some limitations, the present meta-analysis provides statistical evidence indicating a lack of association between Arg72Pro polymorphism and ovarian cancer risk.

摘要

该基因产物是细胞生长的重要调节因子和肿瘤抑制因子。Arg72Pro多态性与卵巢癌风险之间的关联已得到广泛研究，但结果相互矛盾。因此，我们在PubMed、EMBASE和中国生物医学数据库中搜索了关于Arg72Pro多态性与卵巢癌风险关系的研究。我们最终的荟萃分析纳入了24项已发表的研究，共3271例病例和6842例对照。汇总结果表明，Arg72Pro多态性与卵巢癌风险之间无显著关联[Pro/Pro与Arg/Arg比较：比值比（OR）=1.04，95%置信区间（CI）=0.81 - 1.34；Arg/Pro与Arg/Arg比较：OR = 1.14，95%CI = 0.96 - 1.36；隐性模型：OR = 1.05，95%CI = 0.90 - 1.22；显性模型：OR = 1.12，95%CI = 0.94 - 1.33；Pro与Arg比较：OR = 1.06，95%CI = 0.93 - 1.20]。同样，分层分析也未发现基因关联。尽管存在一些局限性，但本荟萃分析提供了统计证据，表明Arg72Pro多态性与卵巢癌风险之间缺乏关联。